SCP
TARA icon

Sender Company & Partners’s Protara Therapeutics TARA Stock Holding History

Sender Company & Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-28,502
Closed -$192K – 101
2021
Q4 		$192K Buy
+28,502
New +$197K 0.1% 91

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sender Company & Partners's TARA Position: Q1 2022 in Review

Sender Company & Partners sold out of Protara Therapeutics (TARA) in Q1 2022, closing a stake of 28,502 shares — an estimated $192K sold.

Sender Company & Partners first reported a position in TARA in Q4 2021 and held it in 1 quarter. The position peaked at $192K in Q4 2021. 35 funds tracked by Wall St. Rank hold TARA as of Q1 2022.

  • Sender Company & Partners reported no remaining Protara Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 28,502 Protara Therapeutics shares in Q1 2022, an estimated $192K.
  • Sender Company & Partners first reported a position in Protara Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Protara Therapeutics position peaked at $192K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.